Frataxin production may be stimulated through the use of erythropoietin, a naturally occurring protein. In 2010, an Austrian research team

In June 2011, Edison Pharmaceuticals announced preliminary results from a 28-day phase 2a clinical trial of its experimental compound EPI-A0001

Antioxidants are designed to offer some protection against cell damage by chemicals known as free radicals and to enhance the

In the 1990s, the identification of mutations in the frataxin gene (from which frataxin protein is produced) as the underlying